Usual Nicotine Content Cigarettes

PreclinicalSmall molecule

Usual Nicotine Content Cigarettes is one of 17 small molecule programs targeting Anxiety Disorder. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anxiety DisorderActive, not recruiting

Anxiety DisorderPreclinical

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Anxiety Disorder

#DrugCompanyPhaseTrials

Brintellix

Takeda

Approved

2 2

Vyvanse

Takeda

Approved

1 3

Adhansia Xr

Novartis

Approved

1 4

Buspar

Cymbalta

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Approved

2 7

Inderal

WWyeth-Lederle Vaccines

Approved

1 8

Mifeprex

DDanco

Approved

1 9

Xanax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 10

Pitocin

RRetrophin

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Anxiety Disorder1 trial

Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders

Completed·MMilton S. Hershey Medical Center·N/A·NCT01928758·245 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Usual Nicotine Content Cigarettes. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Usual Nicotine Content Cigarettes compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Usual Nicotine Content Cigarettes. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Milton S. Hershey Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMilton S. Hershey Medical Center

Usual Nicotine Content Cigarettes

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Anxiety Disorder1 trial

References

Drug Info

Quick Facts

Related News